Five Prime Therapeutics Inc. (FPRX)

17.00
0.01 0.06
NASDAQ : Health Technology
Prev Close 17.01
Open 16.97
Day Low/High 16.60 / 17.05
52 Wk Low/High 15.66 / 48.87
Volume 253.56K
Avg Volume 443.00K
Exchange NASDAQ
Shares Outstanding 35.21M
Market Cap 621.09M
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Five Prime Therapeutics To Present At Jefferies 2018 Global Healthcare Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Francis Sarena, Chief Strategy Officer, will present at the Jefferies 2018 Global...

Five Prime Therapeutics Appoints Bryan Irving, Ph.D., As Chief Scientific Officer

Five Prime Therapeutics Appoints Bryan Irving, Ph.D., As Chief Scientific Officer

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Bryan Irving, Ph.

Five Prime Therapeutics Announces First Quarter 2018 Financial Results

Five Prime Therapeutics Announces First Quarter 2018 Financial Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the fiscal...

Five Prime To Present At 2018 ASCO Annual Meeting

Five Prime To Present At 2018 ASCO Annual Meeting

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it will present two posters during the 2018 American Society of...

Five Prime Therapeutics To Announce First Quarter 2018 Financial Results And Host Conference Call On May 8

Five Prime Therapeutics To Announce First Quarter 2018 Financial Results And Host Conference Call On May 8

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2018 financial results on Tuesday, May 8, 2018,...

Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that it initiated patient dosing in its Phase 1...

Five Prime Therapeutics Announces Oral Presentation On FPA150 At The 2018 AACR Annual Meeting

Five Prime Therapeutics Announces Oral Presentation On FPA150 At The 2018 AACR Annual Meeting

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Charles D.

First Week of FPRX May 18th Options Trading

First Week of FPRX May 18th Options Trading

Investors in Five Prime Therapeutics, Inc saw new options become available this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

Five Prime Therapeutics Licenses New Target To UCB Originating From Its Proprietary Protein Discovery Platform

Five Prime Therapeutics Licenses New Target To UCB Originating From Its Proprietary Protein Discovery Platform

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced UCB has elected to exclusively...

Relative Strength Alert For Five Prime Therapeutics

Relative Strength Alert For Five Prime Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Five Prime Therapeutics Announces Executive Change

Five Prime Therapeutics Announces Executive Change

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Marc Belsky, Senior Vice...

Five Prime Therapeutics To Present At Cowen And Company 38th Annual Health Care Conference

Five Prime Therapeutics To Present At Cowen And Company 38th Annual Health Care Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer,...

Five Prime Announces Fourth Quarter And Full Year 2017 Financial Results

Five Prime Announces Fourth Quarter And Full Year 2017 Financial Results

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported...

Five Prime Therapeutics Announces Closing Of Upsized Public Offering

Five Prime Therapeutics Announces Closing Of Upsized Public Offering

Underwriters Fully Exercise Option to Purchase Additional Shares

Five Prime Therapeutics Announces $25 Million Payment By Bristol-Myers Squibb For Cabiralizumab Development Milestone

Five Prime Therapeutics Announces $25 Million Payment By Bristol-Myers Squibb For Cabiralizumab Development Milestone

Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer

Five Prime Therapeutics Submits Investigational New Drug Application For Novel B7-H4 Antibody FPA150

Five Prime Therapeutics Submits Investigational New Drug Application For Novel B7-H4 Antibody FPA150

Dual mechanism of action blocks a T cell checkpoint pathway and delivers enhanced ADCC against B7-H4-expressing tumor cells

First Week of February 16th Options Trading For Five Prime Therapeutics (FPRX)

First Week of February 16th Options Trading For Five Prime Therapeutics (FPRX)

Investors in Five Prime Therapeutics, Inc saw new options become available this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new February 16th contracts and identified one put and one call contract of particular interest.

Commit To Purchase Five Prime Therapeutics At $17.50, Earn 21% Annualized Using Options

Commit To Purchase Five Prime Therapeutics At $17.50, Earn 21% Annualized Using Options

Investors considering a purchase of Five Prime Therapeutics, Inc shares, but tentative about paying the going market price of $22.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $17.50 strike, which has a bid at the time of this writing of $1.65.

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement For FPA144 Anti-FGFR2b Antibody In Greater China And Global Strategic Development Collaboration

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement For FPA144 Anti-FGFR2b Antibody In Greater China And Global Strategic Development Collaboration

Planned global Phase 3 FIGHT trial in front-line gastric and gastro-esophageal junction cancers to include sites in China where disease incidence is the highest in the world

TheStreet Quant Rating: D (Sell)